



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/587,412
				Filing Date	July 27, 2006
				First Named Inventor	Anna Helgadottir
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	12	Attorney Docket Number	30847/40792A

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US-2002/0107276	08-08-2002	Isakson et al.	
	A2	US-2003/0004101	01-02-2003	Rogers	
	A3	US-2003/0194721	10-16-2003	Mikita et al.	
	A4	US-2003/0225155	12-04-2003	Fernandez-Pol et al.	
	A5	US-2004/0014759	01-22-2004	Picard et al.	
	A6	US-2004/0053983	03-18-2004	Barvian et al.	
	A7	US-2006/0154912	07-13-2006	Harter et al.	
	A8	US-3,983,140	09-28-1976	Endo et al.	
	A9	US-4,231,938	11-04-1980	Monaghan et al.	
	A10	US-4,346,227	08-24-1982	Terahara et al.	
	A11	US-4,376,110	03-08-1983	David et al.	
	A12	US-4,444,784	04-24-1984	Hoffman et al.	
	A13	US-4,450,171	05-22-1984	Hoffman et al.	
	A14	US-4,499,289	02-12-1985	Baran et al.	
	A15	US-4,613,610	09-23-1986	Wareing	
	A16	US-4,647,576	03-03-1987	Hoeffle et al.	
	A17	US-4,681,893	07-21-1987	Roth	
	A18	US-4,683,202	07-28-1987	Mullis	
	A19	US-4,686,237	08-11-1987	Anderson	
	A20	US-4,736,866	04-12-1988	Leder et al.	
	A21	US-4,870,009	09-26-1989	Evans et al.	
	A22	US-4,873,191	10-10-1989	Wagner et al.	
	A23	US-4,970,215	11-13-1990	Mohrs et al.	
	A24	US-4,996,230	02-26-1991	Gapinski	
	A25	US-5,006,530	04-09-1991	Angerbauer et al.	
	A26	US-5,011,930	04-30-1991	Fujikawa et al.	
	A27	US-5,030,447	07-09-1991	Joshi et al.	
	A28	US-5,059,609	10-22-1991	Eggler et al.	
	A29	US-5,126,971	06-30-1992	Lin et al.	
	A30	US-5,143,854	09-01-1992	Pirrung et al.	
	A31	US-5,177,080	01-05-1993	Angerbauer et al.	
	A32	US-5,180,589	01-19-1993	Joshi et al.	
	A33	US-5,260,440	11-09-1993	Hirai et al.	
	A34	US-5,273,995	12-28-1993	Roth	
	A35	US-5,288,644	02-22-1994	Beavis et al.	
	A36	US-5,288,743	02-22-1994	Brooks et al.	
	A37	US-5,288,751	02-22-1994	Brooks et al.	
	A38	US-5,298,512	03-29-1994	Eggler et al.	
	A39	US-5,306,820	04-26-1994	Decker et al.	
	A40	US-5,354,772	10-11-1994	Kathawala	
	A41	US-5,356,896	10-18-1994	Kabadi et al.	
	A42	US-5,384,261	01-24-1995	Winkler et al.	
	A43	US-5,385,929	01-31-1995	Bjorge et al.	
	A44	US-5,403,860	04-04-1995	Kurabayashi et al.	
	A45	US-5,424,186	06-13-1995	Fodor et al.	
	A46	US-5,506,219	04-09-1996	Robl	
	A47	US-5,527,827	06-18-1996	Delorme et al.	
	A48	US-5,549,150	08-27-1996	Williams	
	A49	US-5,549,879	08-27-1996	Chow	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/587,412
				Filing Date	July 27, 2006
				First Named Inventor	Anna Helgadottir
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	12	Attorney Docket Number	30847/40792A

	A50	US-5,559,134	09-24-1996	Buchmann et al.	
	A51	US-5,576,338	11-19-1996	Friesen et al.	
	A52	US-5,616,596	04-01-1997	Basha et al.	
	A53	US-5,622,985	04-22-1997	Olukotun et al.	
	A54	US-5,641,789	06-24-1997	Marfat	
	A55	US-5,686,104	11-11-1997	Mills et al.	
	A56	US-5,691,322	11-25-1997	Robl	
	A57	US-5,753,675	05-19-1998	Wattanasin	
	A58	US-5,763,646	06-09-1998	Kumar et al.	
	A59	US-5,763,653	06-09-1998	Khanna et al.	
	A60	US-5,939,529	08-17-1999	Potempa	
	A61	US-5,969,156	10-19-1999	Briggs et al.	
	A62	US-5,981,559	11-09-1999	Nagaoka et al.	
	A63	US-5,990,148	11-23-1999	Isakson et al.	
	A64	US-6,040,147	03-21-2000	Ridker et al.	
	A65	US-6,126,971	10-03-2000	Mills et al.	
	A66	US-6,166,031	12-26-2000	Eggler et al.	
	A67	US-6,316,460	11-13-2001	Creekmore et al.	
	A68	US-6,436,924	08-20-2002	Poppe et al.	
	A69	US-6,506,876	01-14-2003	Chandrakumar et al.	
	A70	US-6,521,747	02-18-2003	Anastasio et al.	
	A71	US-6,531,279	03-11-2003	Blumenfeld et al.	
	A72	US-6,544,730	04-08-2003	Deininger et al.	
	A73	US-6,576,669	06-10-2003	Anderskewitz et al.	
	A74	US-6,589,959	07-08-2003	Taylor et al.	
	A75	US-6,797,475	09-28-2004	Barnes et al.	
	A76	US-6,803,379	10-12-2004	Fernandez-Pol et al.	
	A77	US-6,825,015	11-30-2004	Pflaum et al.	
	A78	US-6,838,566	01-04-2005	Pflaum et al.	
	A79	US-7,034,000	04-25-2006	Rogers	
	A80	US-RE37,314	08-07-2001	Hirai et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	CA-2337571	08-20-2002	Asta Medica AG		
	B2	DE-10007203	08-23-2001	Asta Medica AG		
	B3	DE-04118014	12-03-1992	Rhone-Paulenc Rorer GmbH		
	B4	DE-04118173	12-10-1992	Rhone-Poulenc Rorer GmbH		
	B5	DE-04127842	02-25-1993	Rhone-Poulenc Rorer GmbH		
	B6	EP-0 344 519	04-14-1993	Bayer AG		
	B7	EP-0 360 246	03-28-1990	G.D. Searle & Co.		
	B8	EP-0 509 359	02-28-1996	Bayer AG		
	B9	EP-0 518 819	12-16-1992	Ciba-Geigy AG		
	B10	EP-0 703 216	03-27-1996	ONO Pharmaceutical Co., Ltd.		
	B11	EP-0 870 762	10-14-1998	Santen Pharmaceutical Co., Ltd		
	B12	EP-0 947 502	10-06-1999	Santen Pharmaceutical Co., Ltd.		
	B13	JP-00355551	12-26-2000	Nikken Chemicals Co. Ltd.		
	B14	JP-03227922	10-08-1991	Teijin Ltd.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/587,412
				Filing Date	July 27, 2006
				First Named Inventor	Anna Helgadottir
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	3	of	12	Attorney Docket Number	30847/40792A

	B15	JP-06072947	03-15-1994	ONO Pharmaceut Co Ltd.		
	B16	WO-1994/00420	01-06-1994	The Scripps Research Institute		
	B17	WO-1995/18610	07-13-1995	Biftu et al.		
	B18	WO-1996/11192	04-18-1996	G.D. Searle & Co.		
	B19	WO-1997/29774	08-21-1997	G.D. Searle & Co.		
	B20	WO-1997/29775	08-21-1997	G.D. Searle & Co.		
	B21	WO-1998/09943	03-12-1998	Santen Pharmaceutical Co., Ltd.		
	B22	WO-1998/11085	03-19-1998	Pfizer Inc.		
	B23	WO-1998/13347	04-02-1998	Novartis AG		
	B24	WO-1998/40354	09-17-1998	G.D. Searle & Co.		
	B25	WO-1998/40364	09-17-1998	G.D. Searle & Co.		
	B26	WO-1998/40370	09-17-1998	G.D. Searle & Co.		
	B27	WO-1998/42345	10-01-1998	Eli Lilly and Company		
	B28	WO-1998/43954	10-08-1998	Santen Pharmaceutical Co., LTD.		
	B29	WO-1999/52942	10-21-1999	Genset		
	B30	WO-2000/43001	07-27-2000	British Biotech Pharmaceuticals LTD.		
	B31	WO-2000/50577	08-31-2000	Jesper Z. Haeggstrom		
	B32	WO-2000/59864	10-12-2000	Institut Natl. De La Sante Et De LaRecherche Medicale		
	B33	WO-2001/34199	05-17-2001	Eli Lilly and Company		
	B34	WO-2001/57025	08-09-2001	Pfizer Products Inc.		
	B35	WO-2001/96347	12-20-2001	Bristol-Myers Squibb Company		
	B36	WO-2002/05825	01-24-2002	Bristol-Myers Squibb Company		
	B37	WO-2002/60378	08-08-2002	Ni-Tromed, Inc.		
	B38	WO-2003/35670	05-01-2003	The Mehrabian et al.		
	B39	WO-2003/37349	05-08-2003	Merck Patent GMBH		
	B40	WO-2003/63781	08-07-2003	Merck & Co., Inc.		
	B41	WO-2003/82191	10-09-2003	Merck & Co., Inc.		
	B42	WO-2003/86282	10-23-2003	Ni-Tromed, Inc.		
	B43	WO-2003/103602	12-18-2003	Ni-Tromed, Inc.		
	B44	WO-2004/02409	01-08-2004	Ni-Tromed, Inc.		
	B45	WO-2004/12686	02-12-2004	Ni-Tromed, Inc.		
	B46	WO-2004/24186	03-25-2004	Ni-Tromed, Inc.		
	B47	WO-2004/35741	04-29-2004	deCode Genetics EHF		
	B48	WO-2004/47648	06-10-2004	Gary Tsaur		
	B49	WO-2004/55520	07-01-2004	One Way Liver Genomics, S.L.		
	B50	EP-0 065 835	11-13-1985	Sankyo Company Limited		
	B51	EP-0 142 146	05-22-1985	Merck & Co. Inc.		
	B52	EP-0 221 025	05-06-1987	Sandoz AG		
	B53	EP-0 276 064	07-27-1988	Eli Lilly & Co.		
	B54	EP-0 405 116	01-02-1991	ONO Pharmaceutical Co.		
	B55	EP-0 419 049	03-27-1991	Merck Frosst Canada Inc.		
	B56	EP-0 422 329	04-17-1991	EURO Celtique SA		
	B57	EP-0 466 452	01-15-1992	Imperial Chemical Industry PLC et al.		
	B58	EP-0 549 879	07-07-1993	Bayer Ag		
	B59	EP-0 623 614	11-09-1994	Zeneca Ltd et al.		
	B60	EP-0 743 064	11-20-1996	Eli Lilly & Co.		
	B61	FR-2596393	10-02-1987	Sanofi SA		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/587,412
				Filing Date	July 27, 2006
				First Named Inventor	Anna Helgadottir
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	4	of	12	Attorney Docket Number	30847/40792A

	B62	GB-2055100	02-25-1981	Sankyo Co.		
	B63	GB-2073199	10-14-1981	Sankyo Co. Ltd.		
	B64	GB-2205837	12-21-1988	Squibb & Sons Inc.		
	B65	JP-03238407	08-27-2003	Nissan Chem Ind Ltd.		
	B66	WO-1986/03488	06-19-1986	Sandoz AG		
	B67	WO-1986/07054	12-04-1986	Sandoz AG		
	B68	WO-1992/03132	03-05-1992	Abbott Lab		
	B69	WO-1995/00487	01-05-1995	Smithkline Beecham PLC		
	B70	WO-1995/11995	05-04-1995	Affymax Tech Nv et al.		
	B71	WO-1996/27585	09-12-1996	Santen Pharmaceutical Co., Ltd.		
	B72	WO-1996/41625	12-27-1996	G.D. Searle & Co.		
	B73	WO-2001/17528	03-15-2001	Nitromed Inc.		
	B74	WO-2004/28341	04-08-2004	deCode Genetics EHF		
	B75	WO-2004/35746	04-29-2004	deCode Genetics EHF		
	B76	WO-2005/27886	03-31-2005	deCode Genetics EHF		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	C1	AHMED et al., Serial intravascular ultrasound assessment of the efficacy of Intracoronary γ-radiation therapy for preventing recurrence in very long, diffuse, in-stent restenosis lesions, Circulation, 104:856-859, 2001.		
	C2	AIELLO et al., Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice, Arterioscler. Thromb. Vasc. Biol., 22:443-449, 2002.		
	C3	ALLEN et al., Differential leukotriene constrictor responses in human atherosclerotic coronary arteries, Circulation, 97:2406-2413, 1998.		
	C4	ALLEN et al., Enhanced excretion of urinary leukotriene E4 in coronary artery disease and after coronary artery bypass surgery, Coronary Artery Disease, 4:899-904, 1993.		
	C5	ASKONAS et al., Pharmacological characterization of SC-57461A (3-[Methyl[3-[4-(Phenylmethyl)Phenoxy]Propyl]Amino]Propanoic Acid HCl), a potent and selective inhibitor of leukotriene A4 hydrolase I: <i>in vitro</i> studies, JPET, 300:577-582, 2002.		
	C6	BAKR et al., 5-Lipoxygenase and leukotriene A4 hydrolase Expression in primary nephrotic syndrome, Pediatr. Nephrol., 19:396-399, 2004.		
	C7	BARONE et al., Time-related changes in myeloperoxidase activity and leukotriene B4 receptor binding reflect leukocyte influx in cerebral focal stroke, Mol. Chem. Neuropathol., 24:13-30, 1995.		
	C8	BARTH, Which tools are in your cardiac workshop? carotid ultrasound, endothelial function, and magnetic resonance imaging, Am. J. Cardiol., 87:8A-14A, 2001.		
	C9	BATKAI et al., Inhibition of 4-lipoxygenase improves regional myocardial function after repetitive ischemia in the rat heart, Pfluegers Archive, 430:R18, 1995.		
	C10	BERMUDEZ et al, Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women, Arterioscler. Thromb. Vasc. Biol., 22:1668-1673, 2002.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/587,412
				Filing Date	July 27, 2006
				First Named Inventor	Anna Helgadottir
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	5	of	12	Attorney Docket Number	30847/40792A

	C11	BIRKE et al., <i>In vitro</i> and <i>in vivo</i> pharmacological characterization of BIIL 284, a novel and potent leukotriene B4 receptor antagonist, JPET, 297:458-466, 2001.	
	C12	BLAKE et al, C-Reactive protein, subclinical atherosclerosis, and risk of cardiovascular events, Arterioscler. Thromb. Vasc. Biol., 22:1512-1513, 2002.	
	C13	BLAKE et al., Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels, JACC, 40:49-55, 2002.	
	C14	BOYD et al., N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2, Bioorg. Med. Chem. Lett., 10:2557-2561, 2000.	
	C15	BRENNAN et al., Prognostic value of myeloperoxidase in patients with chest pain, N. Eng. J. Med., 349:1595-1604, 2003.	
	C16	BUFFON et al., Widespread coronary inflammation in unstable angina, N. Eng. J. Med., 1:5-12, 2002.	
	C17	BYRUM et al., Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A4 hydrolase-deficient mice, J. Immunol., 163:6810-6819, 1999.	
	C18	CARRY et al., Increased urinary leukotriene excretion in patients with cardiac ischemia; <i>In vivo</i> evidence for 5-lipoxygenase activation, Circulation, 85:232-236, 1992.	
	C19	CASLAKE et al., Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease, Curr. Opin. Lipidol., 14:347-352, 2003.	
	C20	CHANG et al., C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids, PNAS, 99:13043-13048, 2002.	
	C21	CHEN et al., Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin, J. Nat. Cancer. Institute, 95:1053-1060, 2003.	
	C22	COLLINS et al., Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions, Lancet, 363:757-767, 2004.	
	C23	CYRUS et al., Effect of low-dose aspirin on vascular inflammation, plaque stability, and arterogenesis in low-density lipoprotein receptor-deficient mice, Circulation, 106:1282-1287, 2002.	
	C24	DAHLEN et al., Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 10005, Thorax, 52:342-347, 1997.	
	C25	DANESH et al., C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease, N. Eng. J. Med., 350:1387-1397, 2004.	
	C26	DAVIDSON, Introduction: utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agents, Am. J. Cardiol., 87:1A-7A, 2001.	
	C27	DE CATERINA et al., Leukotriene B4 production in human atherosclerotic plaques, Biochim. Acta, 47:S182-85, 1988.	
	C28	DEVILLIER et al., Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update, Pharmacol. Res., 40:15-29, 1999.	
	C29	DIB et al., A comprehensive genetic map of the human genome based on 5,264 microsatellites, Nature, 380:152-154, 1996.	
	C30	DOGGEN et al., C-reactive protein, cardiovascular risk factors and the association with myocardial infarction in men, J. Intern. Med., 248:406-414, 2000.	
	C31	DRAZEN et al., Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment, Nat. Genet., 22:168-170, 1999.	
	C32	DWYER et al., Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis, N. Eng. J. Med., 350:29-37, 2004.	
	C33	EBERHARD et al., Leukotriene A4-hydrolase expression and leukotriene B4 levels in chronic inflammation of bacterial origin: immunohistochemistry and reverse-phase high-performance liquid chromatography analysis of oral mucosal epithelium, Virchows Arch., 440:627-634, 2002.	
	C34	FAULER et al., Cardiovascular effects of leukotrienes, Cardiovasc. Drugs Ther., 3:499-505, 1989.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/587,412
				Filing Date	July 27, 2006
				First Named Inventor	Anna Helgadottir
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	6	of	12	Attorney Docket Number	30847/40792A

C35	FELTENMARK et al., Diverse expression of cytosolic phospholipase A2, 5-lipoxygenase and prostaglandin H synthase 2 in acute pre-B-lymphocytic leukaemia Cells, British J. of Haematology, 90:585-594, 1995.	
C36	FISCHER et al., Effect of a novel 5-lipoxygenase activating protein inhibitor, BAYx 1005, on asthma induced by cold dry air, Thorax, 52:1074-1077, 1997.	
C37	FOLCIK et al., Lipoxygenase Contributes to the Oxidation of Lipids in Human Atherosclerotic Plaques, J Clin Invest, 96:504-510, 1995	
C38	FOLCO et al., Leukotrienes in cardiovascular diseases, Am. J. Respir. Crit. Care. Med., 161:S112-S116, 2000.	
C39	FRENETTE et al., Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors, Bioorg. Med. Chem. Lett., 9:2391-2396, 1999.	
C40	FRIEDRICH et al., Mechanisms of leukotriene B4-triggered monocyte adhesion, Arterioscler. Thromb. Vasc. Biol., 23:1761, 2003.	
C41	FUNK et al., Molecular cloning and amino acid sequence of leukotriene A4 hydrolase, PNAS, 84:6677-6681, 1987.	
C42	FUNK, Prostaglandins and leukotrienes: advances in eicosanoid biology, Science, 294:1871-1875, 2001.	
C43	GenBank accession number Z24370, H. sapiens (D13S289) DNA segment containing (CA) repeat; clone AFM321xb1, 28 November 1994.	
C44	GenBank accession number Z52271, H.sapiens (D13S1238) DNA segment containing (CA) repeat; clone AFMa142zb5, 9 September 2004.	
C45	GOMPERTZ et al., A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD, Chest, 122:289-94, 2002.	
C46	HAGENAARS et al., Rationale and design for the SARIS trial; effect of statin on atherosclerosis and vascular remodeling assessed with intravascular sonography, Cardiovasc. Drugs Ther., 15:339-343, 2001.	
C47	HATZELMANN et al., Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system: implications for the function of 5-lipoxygenase activating protein, Biochem. Pharmacol., 47:2259-2268, 1994.	
C48	HEINZMANN et al., Studies on linkage and association of atopy with the chromosomal region 12q13-24, Clin. Exp. Allergy, 30:1554-1561, 2000.	
C49	HELGADOTTIR et al., Familial clustering of myocardial infarction in the Icelandic population: evidence for genetic components, Am. J. Hum. Gen., 84:A205:1128, 1999.	
C50	HELGADOTTIR et al., The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke, Nat. Genet., 36:233-239, 2004.	
C51	IN et al., Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription, J. Clin. Invest., 99:1130-1137, 1997.	
C52	ISHIZAKA et al., Increased leukotriene A4 hydrolase expression in the heart of angiotensin II-induced hypertensive rat, FEBS Lett., 463:155-159, 1999.	
C53	JONSDOTTIR et al., Incidence and prevalence of recognised and unrecognised myocardial infarction in women, Eur. Heart J., 19:1011-1018, 1998.	
C54	KACHUR et al., Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A4 hydrolase II: <i>in vivo</i> studies, JPET, 300:583-587, 2002.	
C55	KAISER et al., Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation, Blood, 104:340-349, 2004.	
C56	KANAYAMA et al., A new Prostacyclin analog, KP-10614, inhibits platelet-polymorphonuclear leukocyte interaction and limits experimental infarct size in rat heart, JPET, 266:344-349, 1993.	
C57	KEANEY, JR. et al, The value of inflammation for predicting unstable angina, N. Eng. J. Med., 347:55-57, 2002.	
C58	KOLASA et al., Synthesis of indolylalkoxyiminoalkylcarboxylates as leukotriene biosynthesis Inhibitors, Bioorg Med Chem, 5:507-514, 1997.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/587,412	
			Filing Date	July 27, 2006	
			First Named Inventor	Anna Helgadottir	
			Art Unit	Not Yet Assigned	
			Examiner Name	Not Yet Assigned	
Sheet	7	of	12	Attorney Docket Number	30847/40792A

	C59	KOSHINO et al., Novel Polymorphism of the 5-lipoxygenase Activating Protein (FLAP) promoter gene associated with asthma, Mol. Cell. Biol. Res. Com., 2:32-35, 1999.	
	C60	KRISTJANSSON et al., Improved one-year survival after acute myocardial infarction in Iceland between 1986 and 1996, Cardiology, 91:210-214, 1999.	
	C61	KUHN et al., Amino acids differences in the deduced 5-lipoxygenase sequence of CAST atherosclerosis-resistance mice confer impaired activity when introduced into the human ortholog, Arterioscler. Thromb. Vasc. Biol., 23:1072-1076, 2003.	
	C62	KURIBAYASHI et al., Inhibitory effects of a phosphate diester of α -tocopherol and ascorbic acid (EPC-K1) on myocardial infarction in rats, Int. J. Tiss. Reac., 18:73-79, 1996.	
	C63	LAM et al., Leukotriene C4 uses a probenecid-sensitive export carrier that does not recognize leukotriene B4, PNAS USA, 89:11598-11602, 1992.	
	C64	LEHR et al., Involvement of 5-lipoxygenase products in cigarette smoke-induced leukocyte/endothelium interaction in hamsters, Int. J. Microcirc. Clin. Exp., 12:61-73, 1993.	
	C65	MAGEE et al., An integrated pharmacokinetic/pharmacodynamic (PK/PD) model for SB-480848 inhibition of plasma lipoprotein-associated phospholipase A2 (LP-PLA2) enzyme activity in human, Am. Soc. Clin. Pharm. Ther., Abstract PIII-87, 2003.	
	C66	MEHRABIAN et al., Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice, Circ. Res., 91:120-126, 2002.	
	C67	MENEGATTI et al., Gene expression of 5-lipoxygenase and LTA4 hydrolase in renal tissue of nephrotic syndrome patients, Clin. Exp. Immunol., 116:347-353, 1999.	
	C68	MONTERO et al., LTA4 hydrolase expression during glomerular inflammation: correlation of immunohistochemical localization with cytokine regulation, Adv. Exp. Med. Biol., 449-454, 1999.	
	C69	MUELLER et al., Leukotriene A4 hydrolase, mutation of tyrosine 378 allows conversion of leukotriene A4 into an isomer of leukotriene B4, J. Biol. Chem., 271:24345-24348, 1996.	
	C70	MULLER-PEDDINGHAUS et al., BAY X1005, A new inhibitor of leukotriene synthesis: <i>in vivo</i> inflammation pharmacology and pharmacokinetics, J. Pharmacol. Exp. Ther., 267:51-57, 1993.	
	C71	MULLER-PEDDINGHAUS et al., BAY X1005, A new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics, J. Lipid. Mediat., 6:245-248, 1993.	
	C72	MULLER-PEDDINGHAUS, R., Potential anti-inflammatory effects of 5-lipoxygenase inhibition - exemplified by the leukotriene synthesis inhibitor Bay X 1005, J. Phys. Pharmacol., 48:529-536, 1997.	
	C73	NISSEN, Coronary angiography and intravascular ultrasound, Am. J. Cardiol., 87:15A-20A, 2001.	
	C74	OESTVANG et al., Role of secretory and cytosolic phospholipase A2 enzymes in lysophosphatidylcholine-stimulated monocyte arachidonic acid release, FEBS Lett., 555:257-262, 2003.	
	C75	OKANO-MITANI et al., Leukotriene A4 hydrolase in peripheral leukocytes of patients with atopic dermatitis, Arch. Dermatol. Res., 288:168-172, 1996.	
	C76	OZAKI et al., Functional SNPs in the lymphotoxin-a gene that are associated with susceptibility to myocardial infarction, Nat. Genet., published online 11 November 2002, doi:10.1038/ng1047, pages 1-5, 2002.	
	C77	PACKARD, et al., Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease, N. Eng. J. Med., 343:1148-1155, 2000.	
	C78	PATERNITI, Investigational new drug applications: the role of the preclinical dossier, Am. J. Cardiol., 81:10F-12F, 1998.	
	C79	PENNING et al., Inhibitors of leukotriene A4 (LTA4) hydrolase as potential anti-inflammatory agents, Cur. Pharm. Design, 7:163-179, 2001.	
	C80	PENNING et al., Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A4 hydrolase, Bioorg. Med. Chem. Lett., 12:3383-3386, 2002.	
	C81	PENNING et al., Structure-activity relationship studies on 1-[2(4-phenylphenoxy) ethyl] pyrrolidine (SC-22716), a potent inhibitor of leukotriene A4 (LTA4) hydrolase, J. Med. Chem., 43:721-735, 2000.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/587,412
				Filing Date	July 27, 2006
				First Named Inventor	Anna Helgadottir
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	8	of	12	Attorney Docket Number	30847/40792A

	C82	PENNING et al., Synthesis of potent leukotriene A4 hydrolase inhibitors: identification of 3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid, J. Med. Chem., 45:3482-3490, 2002.	
	C83	PITT et al., Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease, N. Eng. J. Med., 341:70-76, 1999.	
	C84	POTEMPA et al., Stimulatory effects of the C-reactive protein subunit on monocyte function, including release of IL-1, Protides Biol. Fluids, 34:287-290, 1986.	
	C85	RADMARK, 5-lipoxygenase-derived leukotrienes: mediators also of atherosclerotic inflammation, Arterioscler. Thromb. Vasc. Biol., 23:1140-1142, 2003.	
	C86	RAGGI, Coronary calcium on electron beam tomography imaging as a surrogate marker of coronary artery disease, Am. J. Cardiol., 87:27A-34A, 2001.	
	C87	RETTSTOL et al., C-reactive protein predicts death in patients with previous premature myocardial infarction - a 10 year follow-up study, Atherosclerosis, 160:433-440, 2002.	
	C88	RIDKER et al., Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events, N. Eng. J. Med., 347:1557-1565, 2002.	
	C89	RIDKER et al., C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women, N. Eng. J. Med., 342:836-843, 2000.	
	C90	RIDKER et al., Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels, Circulation, 98:839-844, 1998.	
	C91	ROSENFELD, Leukocyte recruitment into developing atherosclerotic lesions: the complex interaction between multiple molecules keeps getting more complex, Arterioscler. Thromb. Vasc. Biol., 22:361-363, 2002.	
	C92	ROSS, Atherosclerosis - an inflammatory disease, N. Eng. J. Med., 340:115-126, 1999.	
	C93	ROSSONI et al., Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes, J. Pharmacol. Exp. Ther., 276:335-341, 1996.	
	C94	RYBINA et al., Alteration of human leukotriene A4 hydrolase activity after site-directed mutagenesis: serine-415 is a regulatory residue, Biochim. Biophys. Acta, 1438:199-203, 1999.	
	C95	SALA et al., Leukotrienes: lipid bioeffectors of inflammatory reactions, Biochem., 63:84-92, 1998.	
	C96	SALA et al., Monoclonal anti-CD18 antibody prevents transcellular biosynthesis of cysteinyl leukotrienes <i>in vitro</i> and <i>in vivo</i> and protects against leukotriene-dependent increase in coronary vascular resistance and myocardial stiffness, Circulation, 101:1436-1440, 2000.	
	C97	SAMPSON, Leukotrienes in cardiovascular disease, clinical and experimental allergy reviews, Blackwell Science, 1:170-174, 2001.	
	C98	SHEPHERD, Economics of lipid lowering in primary prevention: lessons from the west of Scotland coronary prevention study, Am. J. Cardiol., 87:19B-22B, 2001.	
	C99	SHOWELL et al., The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543, JPET, 285:946-954, 1998.	
	C100	SIGURDSSON et al., Long-term prognosis of different forms of coronary heart disease: the Reykjavik study, Int. J. Epidemiol., 24:58-68, 1995.	
	C101	SIGURDSSON et al., Silent ST-T changes in an epidemiologic cohort study - a marker of hypertension or coronary heart disease, or both: the Reykjavik study, J. Am. Coll. Cardiol., 27:1140-1147, 1996.	
	C102	SMILDE et al., Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial, Lancet, 357:577-581, 2001.	
	C103	SPANBROEK et al., Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis, PNAS USA 100:1238-1243, 2003.	
	C104	STEIN, Laboratory surrogates for anti-atherosclerotic drug development, Am. J. Cardiol., 87:21A-26A, 2001.	
	C105	STEINHILBER, 5-lipoxygenase: a target for antiinflammatory drugs revisited, Curr. Med. Chem., 5:71-85, 1999.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/587,412
				Filing Date	July 27, 2006
				First Named Inventor	Anna Helgadottir
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	9	of	12	Attorney Docket Number	30847/40792A

	C106	SUBBARAO et al., Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms, <i>Arterioscler. Thromb. Vasc. Biol.</i> , 24:369-375, 2003.	
	C107	TAKASE, Change of plasma leukotriene C4 during myocardial ischemia in humans, <i>Clin. Cardiol.</i> , 19:198-204, 1996.	
	C108	TAUBES, Does inflammation cut to the heart of the matter?, <i>Science</i> , 296:242-245, 2002.	
	C109	The SNP Consortium Ltd., SNP report for TSC0806241, gene sequence, (rs1323898), 10 October 2000.	
	C110	THUNNISSEN et al., Crystal structure of human leukotriene A4 hydrolase, a bifunctional enzyme in inflammation, <i>Nat. Struct. Biol.</i> , 8:131-135, 2001.	
	C111	THUNNISSEN et al., Crystal structures of leukotriene A4 hydrolase in complex with captopril and two competitive tight-binding inhibitors, <i>FASEB J.</i> , 16:1648-1650, 2002.	
	C112	TRACY, Inflammation in cardiovascular disease: cart, horse or both revisited, <i>Arterioscler. Thromb. Vasc. Biol.</i> , 22:1514-1515, 2002.	
	C113	TSELEPIS et al., Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase, <i>Artheroscler. Suppl.</i> , 3:57-68, 2002.	
	C114	VERMA et al., A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis, <i>Circulation</i> , 106:913-919, 2002.	
	C115	WALTER et al., Benefits of immediate initiation of statin therapy following successful coronary stent implantation in patients with stable and unstable angina pectoris and Q-wave acute myocardial infarction, <i>Am. J. Cardiol.</i> , 89:1-6, 2002.	
	C116	WANG et al., Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham heart study, <i>Arterioscler. Thromb. Vasc. Biol.</i> , 22:1662-1667, 2002.	
	C117	WATERS et al., Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial Infarction a myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy, <i>Circulation</i> , 106:1690-1695, 2002.	
	C118	WETTERHOLM et al., Leukotriene A4 hydrolase: abrogation of the peptidase activity by mutation of glutamic acid-296, <i>PNAS</i> , 89:9141-9145, 1992.	
	C119	WILLERSON et al., Protection of the myocardium during myocardial Infarction: pharmacologic protection during thrombolytic therapy, <i>Am. J. Cardiol.</i> , 65:35-41, 1990.	
	C120	YAMADA et al., Prediction of the risk of myocardial infarction from polymorphisms in candidate genes, <i>N. Eng. J. Med.</i> , 347:1916-1923, 2002.	
	C121	YANDAVA et al., Cytogenetic and radiation hybrid mapping of human arachidonate 5-lipoxygenase-activating protein (ALOX5AP) to chromosome 13q12, <i>Genomics</i> , 56:131-133, 1999.	
	C122	YOKOMIZO et al., cDNA cloning, expression, and mutagenesis study of leukotriene B4 12-hydroxydehydrogenase, <i>J. Biol. Chem.</i> , 271:2844-2850, 1996.	
	C123	ZHANG et al., Association between myeloperoxidase levels and risk of coronary artery disease, <i>JAMA</i> , 286:2136-2142, 2001.	
	C124	ZHAO et al., The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm, <i>Nat. Med.</i> , 10:966-973, 2004.	
	C125	ASZTALOS et al., Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients, <i>Atherosclerosis</i> , 164:361-369, 2002.	
	C126	BAMSHAD et al., Deconstructing the relationship between genetics and race, <i>Nat. Rev. Genet.</i> , 5:598-609, 2004.	
	C127	BARNHOLTZ-SLOAN et al., Examining population stratification via individual ancestry estimates versus self-reported race, <i>Cancer Epidemiol., Biomarkers & Prevention</i> , 14:1545-1551, 2005.	
	C128	BERRY et al., Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis, <i>Am. Heart. J.</i> , 145:1036-1045, 2003.	
	C129	BLACKIE et al., The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2, <i>Bioorg. Med. Chem. Lett.</i> , 13:1067-1070, 2003.	
	C130	DJURIC et al., Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, <i>Bioorg. Med. Chem. Lett.</i> , 4:811-816, 1994.	
Examiner Signature			Date Considered

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/587,412
				Filing Date	July 27, 2006
				First Named Inventor	Anna Helgadottir
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	10	of	12	Attorney Docket Number	30847/40792A

	C131	DUTHIE et al., Homocysteine, B vitamin status, and cognitive function in the elderly, Am. J. Clin. Nutr., 75:908-913, 2002.	
	C132	FALUSH et al., Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies, Genetics, 164:1567-1587, 2003.	
	C133	GenBank accession number J03459, Human leukotriene A-4 hydrolase mRNA, complete cds, 16 July 1988.	
	C134	GRETARSDOTTIR et al. Localization of a susceptibility gene for common forms of stroke to 5q12, Am. J. Hum. Genet., 70:593-603, 2002.	
	C135	GRETARSDOTTIR et al., The gene encoding phosphodiesterase 4D confers risk of ischemic stroke, Nat. Genet., 35:131-138, 2003.	
	C136	GUDMUNDSSON et al., Localization of a gene for peripheral arterial occlusive disease to chromosome 1p31, Am. J. Hum. Genet., 70:586-592, 2002.	
	C137	HAKONARSON et al, Bi-directional activation between human airway smooth muscle cells and T lymphocytes: role in induction of altered airway responsiveness, J. Immunol., 166:293-303, 2001.	
	C138	HAMILTON et al., Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005, Thorax, 52:348-354, 1997.	
	C139	HATZELMANN et al., Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X1005: implications for biological regulation of 5-lipoxygenase, Advances in Prostaglandin, Thromboxane, and Leukotriene Res., 22:23-31, 1994.	
	C140	HOGGART et al., Control of confounding of genetic associations in stratified population, Am. J. Hum. Genet., 72:1492-1504, 2003.	
	C141	HURLEY et al., Assessing the statins, Aust. Prescr., 22:114-117, 1999.	
	C142	Increased Spending at Vanguard...VML 295 Studies Discontinued, SCRIP World Pharmaceutical News, 2272:13, 1997.	
	C143	International Congress of the Inflammation Research Association (7 th), Novel trends in allergenic and non-allergenic airways inflammation, White Haven, PA, 1994.	
	C144	International Preliminary Examination Report, PCT/US2003/32556, European Patent Office, 21 November 2005.	
	C145	International Preliminary Report on Patentability, PCT/US2004/30582, European Patent Office, 8 December 2005.	
	C146	International Preliminary Report on Patentability, PCT/US2005/03312, European Patent Office, 31 July 2006.	
	C147	International Search Report, PCT/US2003/32556, European Patent Office, 21 October 2004.	
	C148	International Search Report, PCT/US2004/30582, European Patent Office, 23 May 2005.	
	C149	International Search Report, PCT/US2005/03312, European Patent Office, 26 May 2006.	
	C150	International Search Report, PCT/US2006/12073, European Patent Office, 20 March 2007.	
	C151	International Symposium on Medicinal Chemistry (13 th), Paris, Eur. J. Med Chem., 30:190-199, 1994.	
	C152	JACKSON et al., Design, synthesis, and pharmacological evaluation of potent xanthone dicarboxylic acid leukotriene B4 receptor antagonists, J. Med. Chem., 36:1726-1734, 1993.	
	C153	JORDE et al., Genetic variation, classification, and race, Nat. Genet., 36:S28-33, 2004.	
	C154	JORGENSEN et al., Ethnicity and human genetic linkage maps, Am. J. Hum. Genet., 76:276-290, 2005.	
	C155	KREFT et al., Conversion of a cyclooxygenase (CO) inhibitor into a 5-lipoxygenase (LO) inhibitor: a general route to novel orally active anti-inflammatory and anti-allergy drugs, Drugs Exp. Clin. Res., 17:381-387, 1991.	
	C156	KRUGLYAK et al., Parametric and nonparametric linkage analysis: a unified multipoint approach, Am. J. Hum. Genet., 58:1347-1363, 1996.	
	C157	LONG et al., The genetic structure of admixed populations, Genetics, 127:417-428, 1991.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/587,412
				Filing Date	July 27, 2006
				First Named Inventor	Anna Helgadottir
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	11	of	12	Attorney Docket Number	30847/40792A

	C158	MACLEOD et al., No association between Glu/Asp polymorphism of NOS3 gene and ischemic stroke, <i>Neurology</i> , 53:418-420, 1999.	
	C159	MEIKLEJOHN et al., Plasma homocysteine concentrations in the acute and convalescent periods of atherothrombotic stroke, <i>Stroke</i> , 32:57-62, 2001.	
	C160	MORGAN et al., Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study, <i>JAMA</i> , 297(14):1151-1561, 2007.	
	C161	NIH News, National Heart, Lung, and Blood Institute, Update on cholesterol guidelines: more-intensive treatment options for higher risk patients, www.nih.gov/news/pr/jul2004/nhlbi-12.htm , 12 July 2004.	
	C162	NISSEN et al., Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease, <i>N. Eng. J. Med.</i> , 352:29-38, 2005.	
	C163	ONG et al., Protecting the heart: a practical review of the statin studies, <i>Medscape General Medicine</i> , 4(4), 10 December 2002.	
	C164	PARRA et al., Estimating African American admixture proportions by use of population-specific alleles, <i>Am. J. Hum. Genet.</i> , 63:1839-1851, 1998.	
	C165	PEARSON et al., Markers of inflammation and cardiovascular disease, <i>Circulation</i> , 107:499-511, 2003.	
	C166	PENNING et al., Second-generation leukotriene B4 receptor antagonists related to SC-41930: heterocyclic replacement of the methyl ketone pharmacophore, <i>J. Med. Chem.</i> , 38:858-868, 1995.	
	C167	PENNING et al., Synthesis of imidazopyridines and purines as potent inhibitors of leukotriene A4 hydrolase, <i>Bioorg. Med. Chem. Lett.</i> , 13:1137-1139, 2003.	
	C168	PRITCHARD et al., Association mapping in structured populations, <i>Am. J. Hum. Genet.</i> , 67:170-181, 2000.	
	C169	PRITCHARD et al., Inference of population structure using multilocus genotype data, <i>Genetics</i> , 155:945-959, 2000.	
	C170	Quinoline 5-lipoxygenase inhibitors, <i>Cur. Opinion Ther. Patents</i> , 2:2007-2008, 1992.	
	C171	REINER et al., Population structure, admixture, and aging-related phenotypes in African American adults: the cardiovascular health study, <i>Am. J. Hum. Genet.</i> , 76:463-477, 2005.	
	C172	Rhone-Poulenc Rorer's Product Pipeline, <i>SCRIP World Pharmaceutical News</i> , 2168(20), 1996.	
	C173	RIDKER et al., C-reactive protein levels and outcomes after statin therapy, <i>N. Eng. J. Med.</i> , 352:20-28, 2005.	
	C174	RIDKER et al., Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men, <i>N. Eng. J. Med.</i> , 336:973-979, 1997.	
	C175	RIDKER, C-reactive protein: a simple test to help predict risk of heart attack and stroke, <i>Circulation</i> , 108:e81-e85, 2003.	
	C176	ROYAL et al., Changing the paradigm from 'race' to human genome variation, <i>Nat. Genet.</i> , 36:S5-7, 2004.	
	C177	SAITO et al., Multicenter randomised clinical trial of ebselen with aneurysmal subarachnoid hemorrhage, <i>J. Cereb. Blood Flow Metab.</i> , 15:S162, 1995.	
	C178	SCHWARTZ et al., Phase I and pharmacokinetic study of LY293111, an orally available small molecule known to be an LTB4 receptor antagonist, 5-lipoxygenase inhibitor and peroxisome proliferator activated receptor-gamma agonist (PPAR), Abstract 343, 2002 ASCO Annual Meeting.	
	C179	SMITH et al., A high-density admixture map for disease gene discovery in African Americans, <i>Am. J. Hum. Genet.</i> , 74:1001-1013, 2004.	
	C180	STANCU et al., Statins: mechanism of action and effects, <i>J. Cell. Mol. Med</i> , 5:378-387, 2001.	
	C181	TANG et al., Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies, <i>Am. J. Hum. Genet.</i> , 76:268-275, 2005.	
	C182	TERWILLIGER et al., A haplotype-based 'haplotype relative risk' approach to detecting allelic associations, <i>Hum. Hered.</i> , 42:337-346, 1992.	
	C183	The International HapMap Project, A haplotype map of the human genome, <i>Nature</i> , 426:789-796, 2003.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/587,412
				Filing Date	July 27, 2006
				First Named Inventor	Anna Helgadottir
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	12	of	12	Attorney Docket Number	30847/40792A

	C184	TUNSTALL-PEDOE et al., The World Health Organization Monica Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration, J. Clin. Epidemiol., 41:105-114, 1988.	
	C185	WHALLEY et al., Cognitive aging, childhood intelligence, and the use of food supplements: possible involvement of n-3 fatty acids, Am. J. Clin. Nutr., 80:1650-1657, 2004.	
	C186	WHITTEMORE et al, A class of tests for linkage using affected pedigree members, Biometrics, 50:118-127, 1994.	
	C187	Written Opinion of the International Searching Authority, PCT/US2005/03312, European Patent Office, 26 May 2006.	
	C188	Written Opinion of the International Searching Authority, PCT/US2004/30582, European Patent Office, 23 May 2005.	
	C189	Written Opinion of the International Searching Authority, PCT/US2006/12073, European Patent Office, 20 March 2007.	
	C190	YEE et al., Practical synthesis of an enantiomerically pure trans-4,5-disubstituted 2-pyrrolidinone via enzymatic resolution preparation of the LTB4 inhibitor BIRZ-227, J. Org. Chem., 63:326-330, 1998.	
	C191	ANDRESDOTTIR et al., Fifteen percent of myocardial infarctions and coronary revascularizations explained by family history unrelated to conventional risk factors, Eur. Heart J., 23:1655-1663, 2002.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--